Attached files

file filename
8-K - FORM 8-K - KMG CHEMICALS INCd364412d8k.htm

Exhibit 99.1

KMG Chemicals Reports Third Quarter 2012 Results

Consolidation and integration efforts drive 48% year/year diluted EPS increase to $0.34

HOUSTON, TX, June 8, 2012 (BUSINESS WIRE) – KMG Chemicals, Inc. (NASDAQ GS: KMGB), a global provider of specialty chemicals in select markets, today announced financial results for the third fiscal quarter ended April 30, 2012.

2012 Fiscal Third Quarter Highlights

 

   

Net sales were $66.6 million, up 7.6% versus $61.9 million in the third quarter of fiscal 2011, primarily reflecting the impact of recently implemented pricing actions in both the Electronic Chemicals and Wood Treating chemicals businesses.

 

   

Operating income increased 65.9% to $6.9 million from $4.1 million in the third fiscal quarter of 2011. Operating margins were 10.3% in the third quarter of 2012, up from 6.7% in the prior year period.

 

   

Diluted earnings per share were $0.34 per share versus $0.23 per share reported in last year’s third fiscal quarter.

 

   

Net cash provided by operating activities was $8.5 million, compared to net cash used of $459,000 in the same period a year ago.

 

   

Total long-term debt was $28 million, down from $41 million at the end of the preceding quarter and $49.3 million at the end of fiscal 2011. The Company used the proceeds received on the sale of its Animal Health business to repay $10.0 million of the balance during the third quarter of fiscal year 2012.

Neal Butler, President and CEO of KMG, commented, “Our third quarter earnings were up substantially from the preceding quarter and from the prior-year period, reflecting the benefits of our Electronic Chemicals plant consolidation and integration efforts. Targeted pricing actions in our Electronic Chemicals and Wood Treating business segments also benefited results, and enabled us to recoup higher raw materials costs. We ended the quarter in a strong financial position with $5.2 million in cash and a balance sheet with substantial borrowing capacity to fund further growth.”

Business Unit Overviews and Trends

KMG previously had four reportable segments: Electronic Chemicals, Penta, Creosote, and Animal Health. During the first fiscal quarter of 2011, the Company re-evaluated the criteria used to determine operating segments, and concluded that its two Wood Treating product segments met the criteria of a single operating segment. Then on March 1, 2012, the Company sold its Animal Health business. KMG’s reportable segments have been revised to reflect a change from four to two reportable segments: Electronic Chemicals and Wood Treating Chemicals. Prior period information has been reclassified to conform to the current period presentation.


Electronic Chemicals

Net sales in the Electronic Chemicals segment increased 2.4% to $39.4 million in the fiscal third quarter of 2012, as compared to $38.5 million in the third fiscal quarter of 2011. The year-over-year sales increase primarily reflected the positive impact of price increases instituted over the past twelve months. Despite some softening in the European semiconductor market due to economic weakness, our overall sales volumes have remained relatively firm. We expect demand for our electronic chemicals products to improve in calendar 2012, and we will have additional business from a new North American semiconductor fabrication facility that has come on stream.

Segment operating profits improved 146% to $3.9 million, from $1.6 million in the same period a year ago, benefiting from higher product pricing completed over the last twelve months as well as efficiency improvements in our supply chain and the completion of our integration of the General Chemical acquired assets in fiscal 2011.

Wood Treating Chemicals

Net sales in the Wood Treating Chemicals segment increased 16.1% to $27.2 million in the fiscal third quarter of 2012, up from $23.4 million in the third fiscal quarter of 2011. The year-over-year sales increase primarily reflected higher realized pricing for creosote and pentachlorophenol products, although both products also benefited from increased sales volumes. We foresee relatively flat demand in our Wood Treating segment for the remainder of fiscal 2012.

Wood Treating operating income expanded 24.0% in the fiscal third quarter of 2012 to $3.9 million, from $3.2 million in the prior-year period. The increase in operating profits reflected the positive impact of pricing actions implemented to recover previously incurred raw material cost increases, and to a lesser extent, higher sales volumes.

Animal Health Business Sold

On March 1, 2012, KMG completed the sale of the Animal Health business assets to Bayer Healthcare, LLP. In the transaction, KMG sold manufacturing equipment, inventory and product registrations, and retained the real estate at the Elwood, Kansas location. The purchase price was approximately $10.2 million, following the post-closing adjustment for product sold from inventory prior to closing. We are providing manufacturing services to the purchaser under a one year transition services agreement that is renewable for two six-month periods.

Balance Sheet and Cash Flow Overview

John V. Sobchak, CFO of KMG, commented, “At April 30, 2012, total long-term debt declined to $28 million from $41 million at January 31, 2012 and $49.3 million at fiscal 2011 year-end. As of April 30, 2012, our long-term debt consisted of $20 million of fixed-rate notes maturing in December 2014, and $8 million drawn on our $60 million revolving line of credit. Net cash provided by operating activities was $8.5 million in the third fiscal quarter of 2012 and $22.9 million for the nine months of the current fiscal year. Shareholders’ equity was $104.6 million as of April 30, 2012.”


Outlook

Mr. Butler commented, “This quarter’s strong financial performance reflects the progress we have made in integrating acquired electronic chemicals assets, and remains consistent with our prior guidance that results in the second half of fiscal 2012 will show substantial improvement as compared to fiscal 2011. While economic weakness in Europe may temper near-term results in that region, we expect the overall Electronic Chemicals business to be stable in the fiscal fourth quarter. In addition, we do not expect customer demand in our Wood Treating business to show much change from fiscal third quarter levels for the remainder of this fiscal year. As always, we remain active in our search for additional consolidation opportunities in both Electronic Chemicals and Wood Treating Chemicals. We also remain committed to acquiring a new growth platform by fiscal 2014.”

Conference Call

Date: Friday, June 8, 2012

Time: 10:00 am ET

Dial-in: 888-330-6585 (Domestic), 631-813-4882 (International)

Conference ID: 85549353

About KMG

KMG Chemicals, Inc., through its subsidiaries, produces and distributes specialty chemicals to carefully focused markets. The Company grows by acquiring and optimizing stable chemical product lines and businesses with established production processes. Its current operations are focused on the electronic and industrial wood treatment chemical markets. For more information, visit the Company’s web site at www.kmgchemicals.com.

The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, the impact of competitive services and pricing and general economic risks and uncertainties.

Contact

Eric Glover

Manager of Investor Relations

KMG Chemicals, Inc.

713-600-3865


KMG CHEMICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

(In thousands, except for per share amounts)

 

     Three Months Ended     Nine Months Ended  
     April 30,     April 30,  
     2012     2011     2012     2011  

Net sales

   $ 66,579      $ 61,899      $ 205,093      $ 184,660   

 

Cost of sales

     45,973        45,134        148,671        133,545   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     20,606        16,765        56,422        51,115   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Distribution expenses

     7,418        7,413        19,290        20,743   

Selling, general and administrative expenses

     6,320        5,211        18,390        15,861   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     6,868        4,141        18,742        14,511   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Other income (expense)

        

Interest income

     —          —          1        1   

Interest expense

     (504     (571     (1,610     (1,765

Other, net

     (48     50        (195     (140
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other expense, net

     (552     (521     (1,804     (1,904
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Income from continuing operations before income taxes

     6,316        3,620        16,938        12,607   

 

Provision for income taxes

     (2,417     (1,245     (6,643     (4,255
  

 

 

   

 

 

   

 

 

   

 

 

 

Income from continuing operations

     3,899        2,375        10,295        8,352   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Discontinued operations:

        

Gain/(loss) from discontinued operations, before income tax

     182        385        (434     334   

Income tax benefit/(expense)

     (116     (153     101        (139
  

 

 

   

 

 

   

 

 

   

 

 

 

Gain/(loss) from discontinued operations

     66        232        (333     195   

 

Net income

   $ 3,965      $ 2,607      $ 9,962      $ 8,547   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Earnings per share:

        

Basic

        

Income from continuing operations

   $ 0.34      $ 0.21      $ 0.91      $ 0.74   

Gain/(loss) from discontinued operations

     0.01        0.02        (0.03     0.01   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $ 0.35      $ 0.23      $ 0.88      $ 0.75   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Diluted

        

Income from continuing operations

   $ 0.33      $ 0.21      $ 0.89      $ 0.73   

Gain/(loss) from discontinued operations

     0.01        0.02        (0.03     0.01   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $ 0.34      $ 0.23      $ 0.86      $ 0.74   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

Weighted average shares outstanding:

        

Basic

     11,363        11,313        11,355        11,306   

Diluted

     11,539        11,499        11,523        11,484   


KMG CHEMICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands except for share and per share amounts)

 

     April 30,     July 31,  
     2012     2011  
     (Unaudited)        

Assets

    

Current assets

    

Cash and cash equivalents

   $ 5,194      $ 1,826   

Accounts receivable

    

Trade, net of allowance of $16 at April 30, 2012 and $414 at July 31, 2011

     28,840        36,410   

Other

     3,015        3,148   

Inventories, net

     39,995        41,770   

Current deferred tax assets

     721        726   

Prepaid expenses and other

     2,841        2,126   
  

 

 

   

 

 

 

Total current assets

     80,606        86,006   
  

 

 

   

 

 

 

 

Property, plant and equipment, net

     69,526        71,826   

Restricted cash

     1,000        —     

Deferred tax assets

     1,167        1,176   

Goodwill

     3,778        3,778   

Intangible assets, net

     15,057        19,493   

Other assets, net

     3,167        3,099   
  

 

 

   

 

 

 

Total assets

   $ 174,301      $ 185,378   
  

 

 

   

 

 

 

 

Liabilities & stockholders’ equity

    

Current liabilities

    

Accounts payable

   $ 26,371      $ 24,899   

Accrued liabilities

     5,763        4,980   

Book overdraft

     —          2,852   

Income taxes payable

     2,160        44   

Current deferred tax liabilities

     7        7   

Current maturities of long-term debt

     —          8,000   
  

 

 

   

 

 

 

Total current liabilities

     34,301        40,782   
  

 

 

   

 

 

 

 

Long-term debt, net of current maturities

     28,000        41,279   

Deferred tax liabilities

     6,036        5,381   

Other long-term liabilities

     1,359        1,406   
  

 

 

   

 

 

 

Total liabilities

     69,696        88,848   
  

 

 

   

 

 

 

 

Commitments and contingencies

    

 

Stockholders’ equity

    

Preferred stock, $0.01 par value, 10,000,000 shares authorized, none issued

     —          —     

Common stock, $0.01 par value, 40,000,000 shares authorized, 11,371,769 shares issued and outstanding at April 30, 2012 and 11,318,941 shares issued and outstanding at July 31, 2011

     114        113   

Additional paid-in capital

     25,997        25,256   

Accumulated other comprehensive loss

     (2,954     (1,233

Retained earnings

     81,448        72,394   
  

 

 

   

 

 

 

Total stockholders’ equity

     104,605        96,530   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 174,301      $ 185,378   
  

 

 

   

 

 

 


KMG CHEMICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(In thousands)

 

     Nine Months Ended
April 30,
 
     2012     2011  

Cash flows from operating activities

    

Net income

   $ 9,962      $ 8,547   

Adjustments to reconcile net income to net cash provided by operating activities

    

Depreciation and amortization

     5,285        5,688   

Amortization of loan costs included in interest expense

     107        82   

Stock-based compensation expense

     572        441   

Bad debt recovery

            (18

Inventory valuation adjustment

     370        (138

(Gain)/ loss on disposal of property

     (40     131   

Gain on sale of animal health business

     (90       

Deferred income tax expense

     654        546   

Tax benefit from stock-based awards

     (179     (196

Changes in operating assets and liabilities

    

Accounts receivable — trade

     7,159        (1,128

Accounts receivable — other

     138        (676

Inventories

     (4,582     (1,598

Other current and noncurrent assets

     (1,045     (1,127

Accounts payable

     1,503        452   

Accrued liabilities and other

     849        (673

Income taxes payable

     2,268        (361
  

 

 

   

 

 

 

Net cash provided by operating activities

     22,931        9,972   
  

 

 

   

 

 

 

 

Cash flows from investing activities

    

Additions to property, plant and equipment

     (3,887     (5,809

Proceeds from sale of property

     33        59   

Proceeds from sale of animal health business

     10,203          

Change in restricted cash

     (1,000     189   
  

 

 

   

 

 

 

Net cash provided by/ (used in) investing activities

     5,349        (5,561
  

 

 

   

 

 

 

 

Cash flows from financing activities

    

Net payments under revolver credit agreement

     (9,946     (2,093

Principal payments on borrowings on term loan

     (11,333     (6,000

Proceeds from exercise of stock options

     32        200   

Tax benefit from stock-based awards

     179        196   

Book overdraft

     (2,852       

Payment of dividends

     (908     (735
  

 

 

   

 

 

 

Net cash used in financing activities

     (24,828     (8,432
  

 

 

   

 

 

 

 

Effect of exchange rate changes of cash

     (84     220   

Net increase/ (decrease) in cash and cash equivalents

     3,368        (3,801

Cash and cash equivalents at beginning of period

     1,826        4,728   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 5,194      $ 927   
  

 

 

   

 

 

 

 

Supplemental disclosures of cash flow information

    

Cash paid for interest

   $ 1,485      $ 1,746   

Cash paid for income taxes

   $ 3,625      $ 3,748   


Net Sales and Operating Income (Loss) by Segment

($ in thousands; includes effects of rounding)

Segment Net Sales

 

     Three Months Ended April 30,     Nine Months Ended April 30,  
     2012     2011     2012     2011  

Segment

   Net
Sales
     % of Total
Net Sales
    Net
Sales
     % of Total
Net Sales
    Net
Sales
     % of Total
Net Sales
    Net
Sales
     % of Total
Net Sales
 

Electronic Chemicals

   $ 39,422         59   $ 38,509         62   $ 116,396         57   $ 111,303         60

Wood Treating Chemicals

     27,157         41     23,390         38     88,697         43     73,357         40
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Total

   $ 66,579         100   $ 61,899         100   $ 205,093         100   $ 184,660         100
  

 

 

      

 

 

      

 

 

      

 

 

    

Segment Operating Income (Loss)(1)

 

    Three Months Ended April 30,     Nine Months Ended April 30,  
    2012     2011     2012     2011  
Segment   Operating
Income
    % of Segment
Net Sales
    Operating
Income
    % of Segment
Net Sales
    Operating
Income
    % of Segment
Net Sales
    Operating
Income
    % of Segment
Net Sales
 

Electronic Chemicals

  $ 3,904        9.9   $ 1,587        4.1   $ 9,088        7.8   $ 5,943        5.3

Wood Treating Chemicals

    3,932        14.5     3,171        13.6     12,403        14.0     11,372        15.5
 

 

 

     

 

 

     

 

 

     

 

 

   

Total

  $ 7,836        $ 4,758        $ 21,491        $ 17,315     
 

 

 

     

 

 

     

 

 

     

 

 

   

 

(1) Segment income from operations includes allocated corporate overhead expenses.